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ABSTRACT. Gene transfer may be accomplished by the
receptor-mediated endocotosis pathway using transferrin-
polylysime conjugates. For some target cells, however, gene
transfer by this vector is extremely limited, despite the presence
of the appropriate surface receptors, a phenomenon attributed
to lysosomal degradation of endosome-internalized conjugate-
DNA complexes. To enhance DNA escape from the cell vesicle
system and thus augment gene transfer by this route, we have
used the capacity of adenoviruses to disrupt endosomes as part
of their entry mechanism. Adenoviral infection augmented
levels of gene transfer by transferrin-poylysine conjugates in
a-dose-dependent manner: levels ofgene transfer of >2000-fold
above baseline were achieved. Use of the adenovirus in this
context allowed enhanced levels of gene transfer in a variety of
target cells, including cell lines otherwise refractory to gene
transfer by transfirrin-polylysine conjugates. This augmenta-
tion was based on adenoviril-mediated vesicle disruption, a
process independent of viral gene expression. Thus, the devel-
opment of* specific mechanisms to effect release from the
endosome in combination with gene transfer bOy the receptor-
mediated endocyt6sis pathway will increase the utility of this
delivery system by allowing high levels of gene expression in
target cells.
Foreign DNA introduced into eukaryotic cells must traverse
multiple cellular barriers to enter the nucleus where heter-
ologous gene expression can be effected. Various DNA-
mediated gene-transfer methods efficiently accomplish tran-
sit of the initial barrier, the .cell membrane; however, the
specific mechanisms involved in this transfer are frequently
associated with-significant cell toxicity (1, 2). To circumvent
this limitation, strategies have been devised to subvert phys-
iological mechanisms ofmacromolecular transport to achieve
gene transfer. In this regard, DNA delivery has been accom-
plished by means of the receptor-mediated endocytosis path-
way (3, 4). This strategy of gene transfer -employs bifunc-
tional molecular conjugates consisting ofa cognate moiety for
a cell-surface receptor that is covalently linked to a DNA-
binding moiety. When the cognate domain is recognized by
the appropriate cell-surface receptor, the conjugate is inter-
nalized by the receptor-mediated endocytosis pathway,
cotrangporting any foreign DNA that is complexed to the
DNA-binding domain.
Although this method can achieve high levels of gene
expression in selected contexts, in many instances gene
expression is limited despite the presence of an appropriate
surface receptor on the target cell. It has been hypothesized
that this limitation is a consequence of lysosomal targeting of
the endosome-internalized conjugate-DNA complexes (5, 6).
To increase the fraction of DNA that would escape degra-
dation and be expressed within the nucleus, agents to inhibit
lysosomal enzymes have been used. By empidying this
strategy, augmented expression of transferred DNA can be
demonstrated. However, this response is highly idiosyn-
cratic; selected lysosomatropic agents successfully augment
gene expression, whereas others actually inhibit it (6, 7).
Additionally, the response tQ. a given agent can be highly
variable among different target-cell linens (7).
In the present study, we have used an alternative strategy
to augment gene transfer by the receptor-mediated endocy-
tosis pathway. -By using the capacity of adendviruses to
disrupt endosomes as part of their normal mechanism of
target-cell entry, we hypothesized that cointernalized conju-
gate-DNA complexes would be released into the cell cyto-
plasm and, thus, avoid lysosomal degradation. When we
infected cells with a replication-incompetent adenovirus, we
observed very significantly enhanced gene transfer by trans-
ferrin-polylysine conjugates in a variety-of cell lines. Nota-
bly, this augmentation was shown to depend dpon.adenoviral
mechanisms of endosome disruption, consistent with the
concept that entrapment within the vesicle system of the cell
is a major limitation to gene transfer by the receptor-mediated
endocytosis pathway. Thus, the development of strategies to
augment escape from the endosome will likely increase the
applicabilities of gene transfer by this route by allowing
high-level expression of transferred genes in target cells.
MATERIALS AND METHODS
Preparation of Transferrin-Poly(L-Lysine)-DNA Com-
plexes. Human transferrin-poly(L-lysine) conjugates with an
average chain length of 190 lysines (hTfpLl9OB) were pre-
pared, as described (7). The specific ligation was accom-
plished through modification of the transferrin carbohydrate
moiety (8). The DNA plasmid pRSVL containing the Photi-
nus-pyralis luciferase gene under control ofthe Rous sarcoma
virus long terminal repeat enhancer/promoter (9) was used as
a reporter gene. Conjugate-DNA complexes were prepared
by dilution of6 ,4g ofpRSVL DNA in 350 ul ofHBS (150mM
NaCl/20 mM Hepes, pH 7.3) followed by addition to 12 ,ug
of hTfpL19OB diluted in 150 jAl of HBS. Complexes were
allowed to form for 30 min at room temperature before
addition-to cells.
Preparation of Adenoviruses. Adenovirus d1312, a replica-
tion-incompetent strain deleted in the Ela region (10), was
provided by T. Shenk (Department of Molecular Biology,
Princeton University). Propagation of the virus was on the
Ela trans-complementing cell line 293. Large-scale prepara-
tion was exactly as described (11). Purified virus was resus-
pended in storage buffer (100 mM Tris, pH 8.0/100 mM
NaCl/O.1% bovine serum albumin/50%o glycerol) and main-
tained in aliquots at -70'C. Determination of virion concen-
tration was accomplished by UV spectrophotometric analy-
Abbreviation: DMEM, Dulbecco's modified Eagle's medium.
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sis ofextracted viral genomic DNA using the formula that one
absorbance unit (A26) equals 1012 viral particles per ml (12).
Cells and Media. HeLa cells were grown in Dulbecco's
modified Eagle's medium (DMEM)/5% heat-inactivated fetal
calf serum/penicillin at 100 international units per ml/
streptomycin at 100 lug/ml/2 mM glutamine. WI-38, MRC-5,
and KB cells were grown in Eagle's minimal essential me-
dium /10% heat-inactivated fetal calf serum/penicillin at 100
international units/ml/streptomycin at 100 ,ug/ml/10 mM
nonessential amino acids/2 mM glutamine. CFT1, a cystic
fibrosis respiratory epithelial cell line, was from J. Yankaskas
(Division of Pulmonary Diseases, University of North Caro-
lina). These cells were grown in F12-7X medium as described
(J. Yankaskas, personal communication). For gene-transfer
experiments, cells were grown in 6-cm tissue-culture plates
until -50% confluent (5 x 105 cells). Medium was removed,
and 1 ml ofDMEM or Eagle's minimal essential medium/2%
fetal calfserum was added. Conjugate-DNA complexes were
added followed immediately by adenovirus d1312 (0.05-3.2 x
104 particles per cell) or a comparable volume of viral storage
buffer (1-80 pul). Plates were returned to the incubator (5%
C02, 370C) for 1 hr, after which 3 ml ofcomplete medium was
added. After an additional 24 hr, incubation cells were
harvested for analysis of luciferase gene expression. For
CFT1, cells were grown in F12-7X medium lacking human
transferrin supplement for 4 hr before and during gene-
transfer experiments. For sequential binding experiments,
HeLa cells were equilibrated at 40C in 1 ml of DMEM/2%
fetal calf serum. Conjugate-DNA complexes were added, as
before, and plates were incubated at 4°C for 2 hr. After this
period, the plates were washed extensively with ice-cold
DMEM/2% fetal calf serum followed by addition of 2 ml of
the same. Adenovirus d1312 or viral storage buffer was
administered, and the cells were allowed to warm up grad-
ually before being returned to the incubator for an additional
24 hr. After this incubation, cells were harvested for analysis
of luciferase gene expression. Preparation of cellular ex-
tracts, standardization of protein content, and analysis of
luciferase activity were as described (4).
RESULTS
Evaluation of the Effect of Adenoviral Infection on Gene
Transfer by Transferrin-Polylysine Conjugates. Initially, the
effect of increased viral dosage on the capacity of a fixed
amount of conjugate-DNA complex to effect gene transfer
was examined. In this analysis, increased amounts of added
adenovirus resulted in a corresponding increase in the levels
of gene transfer achieved by the transferrin-polylysine con-
jugates (Fig. 1). This adenoviral-mediated augmentation of
gene transfer plateaued at -1 x 104 particles per cell, a figure
corresponding to the approximate number of adenoviral
receptors on the surface of each HeLa cell (13). Levels of
luciferase expression up to 2000-fold over baseline transfer
with transferrin-polylysine conjugate alone were achieved
with the higher number of viral particles. In a second set of
experiments, the capacity of limiting amounts of conjugate-
DNA complex to achieve gene transfer was examined in the
presence of a static dose of adenovirus d1312. Adenoviral
infection-augmented gene transfer by transferrin-polylysine
conjugates over a broad range ofDNA dosages (Fig. 2). The
maximal level of gene expression effected by the conjugate-
DNA complexes alone was achieved by 100-fold less DNA
when adenoviral infection was used to augment delivery.
Determination of the Mechanism of Adenoviral Augmenta-
tion of Gene Transfer by Transferrin-Polylysine Conjugates.
The effect of adenoviral infection on gene transfer was
examined for both uncomplexed DNA and DNA that had
been complexed with polylysine or transferrin-polylysine
conjugates (Fig. 3a). By this analysis, adenoviral infection
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FIG. 1. Effect of adenoviral infection on gene transfer by trans-
ferrin-polylysine conjugates. Viral dosage effect: for complex for-
mation 6 ,ug of luciferase-encoding plasmid DNA (pRSVL) was
mixed with 12 1Lg of human transferrin-polylysine conjugate(hTfpL190B). Conjugate-DNA complex plus variable amounts of the
replication-defective adenovirus d1312 (0.05-3.2 x 104 viral particles
per cell) were added to HeLa cells. Cell lysates were standardized for
total protein content and analyzed for luciferase enzyme activity.
Results are expressed as "light units" per 50 1g of total cellular
protein. Data are the mean oftwo to four separate experiments; error
bars represent SEM.
did not significantly augment transfer ofnaked, uncomplexed
DNA. In marked contrast, transfer of DNA complexed to
polylysine or transferrin-polylysine conjugates was aug-
mented by adenoviral infection. This effect was, however,
much greater for the transferrin-polylysine conjugates. Be-
cause the polycation portion of the conjugate molecule not
only serves to attach transferrin to DNA, but also effects
significant structural changes in the DNA (15), these exper-
iments could not differentiate whether the observed effect
was on the basis of enhanced fluid-phase endocytosis of the
polycation-condensed DNA or augmented delivery of recep-
tor-bound conjugate-DNA complex. To distinguish between
these possibilities, sequential binding experiments were done
(Fig. 3b). Binding of transferrin-polylysine-DNA or polyly-
sine-DNA complexes at low temperature without internal-
ization allowed removal of excess complex in the fluid phase
before adenoviral infection (16). When administered in this
fashion, delivery of the receptor-bound transferrin-
polylysine-DNA complexes was significantly augmented by
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FIG. 2. Conjugate-DNA-complex dosage effect. Logarithmic
dilutions of conjugate-DNA complexes, formed as in Fig. 1, were
added to HeLa cells with or without a fixed dosage of adenovirus
d1312 (1.0 x 104 viral particles per cell). Analysis of luciferase activity
was as before.
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FIG. 3. Adenoviral augmentation of transferrin-polylysine-
mediated gene transfer occurs via the receptor-mediated endocytosis
pathway. (a) Effect of adenoviral infection on transfer ofcomplexed
DNA. Complex formation reactions were set up containing 6 ,&g of
pRSVL DNA without transferrin-polylysine conjugate (DNA), 6 tLg
of pRSVL DNA plus 6 1xg of unconjugated (lysine)hm (DNA + pL),
or 6 ,ug of pRSVL DNA plus 12 1Lg of human transferrin-polylysine
conjugate (DNA + hTfpL190B). The above were added to HeLa
cells with or without added adenovirus d1312 (d1312) (1.0 x 104 viral
particles per cell). Cell extracts were prepared, standardized for total
protein, and analyzed for luciferase enzyme activity as before. (b)
Effect of adenoviral infection on transfer of receptor-bound DNA.
Conjugate-DNA complexes (DNA + hTfpL190B) or polylysine-
DNA complexes (DNA + pL) were bound to HeLa cells without
internalization by incubation at 4TC. Unbound complex was removed
before addition of adenovirus d1312 (1.0 x 104 viral particles per cell)
or a comparable volume of viral storage buffer. Subsequent incuba-
tion was at 370C to permit internalization of bound DNA complexes
and adenoviruses. Analysis of luciferase enzyme activity was as
before. (c) Effect of adenoviral entry on gene transfer by transferrin-
polylysine conjugates. Conjugate-DNA complexes containing 6 ,ug
of pRSVL DNA plus 12 gg of transferrin-polylysine (DNA +
hTfpL190B) were added to HeLa cells with 1.0 x 104 adenovirus
d1312 particles (dI312) or a similar amount of adenovirus d1312 that
had been heat inactivated (d1312 h.i.). Heat inactivation was done by
incubating at 450C for 30 min (14). Analysis of luciferase enzyme
activity was as before.
addition of adenoviral particles, whereas the polylysine-
DNA complexes were not. Thus, it is the entry of DNA by
the receptor-mediated endocytosis pathway that is specifi-
cally enhanced. Next, we analyzed the specific adenoviral
function mediating enhanced gene transfer by the receptor-
mediated endocytosis pathway (Fig. 3c). Mild heat treatment
of virions does not alter the ability of adenoviruses to bind to
target-cell membranes but does ablate their capacity to
disrupt endosomes after internalization (14). Thus, the dis-
tinct effects of viral binding and viral entry could be sepa-
rately evaluated. In this analysis, heat inactivation of the
adenoviruses completely abolished their ability to enhance
receptor-mediated gene transfer. This result suggests that it
is the capacity of the adenoviruses to disrupt endosomes as
part of their entry mechanism which specifically effects
enhancement ofgene delivery by transferrin-polylysine con-
jugates.
Effect of Adenoviral Infection on Gene Transfer by Trans-
ferrin-Polylysine Conjugates in Selected Cell Lines. The pres-
ence of transferrin receptors on target cells is necessary, but
not sufficient, to allow gene transfer by transferrin-
polylysine conjugates. Cell-specific factors relating to the
fate of endosome-internalized conjugate-DNA complexes
appear an extremely important determining factor in the
levels of gene transfer achievable by this route (7). In this
regard, selected cell lines were examined for both gene
transfer by transferrin-polylysine conjugates and augmenta-
tion of receptor-mediated gene delivery by adenoviral infec-
tion (Fig. 4). CFT1 cells showed moderate levels ofluciferase
gene expression after treatment with transferrin-polylysine-
DNA complexes. This level of gene expression was signifi-
cantly augmented by infection with adenovirus d1312. In
marked contrast, KB cells treated with the transferrin-
polylysine conjugates exhibited levels of luciferase gene
expression barely above background levels, despite the pres-
ence oftransferrin receptors (17). Treatment with adenovirus
d1312, however, allowed expression of readily detectable
luciferase levels. Similarly, HeLa cells exhibited levels of
gene expression just above background levels with conju-
gate-DNA complexes. These levels ofgene expression could
also be augmented by adenoviral infection; however, this
effect was much greater than for KB cells. Because HeLa
cells and KB cells possess approximately the same number of
surface receptors for adenovirus (18), it is likely that this
difference in augmentation reflects the number of transferrin
receptors characteristic of each cell type. In marked contrast
to these findings, however, WI-38 and MRC-5, cell lines that
support adenoviral infection very poorly (19), showed very
little augmentation with d1312 over levels achieved by the
conjugate-DNA complexes alone. Adenoviral infection thus
appears to augment gene transfer by conjugate-DNA com-
plexes in instances where gene transfer by the receptor-
mediated endocytosis pathway appears feasible, as for CFT1
cells, and also in some instances where transfer by this route
appears ineffective, as for HeLa and KB cells. The level of
augmentation achieved varies significantly among different
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FIG. 4. Effect of adenoviral infection on gene transfer by trans-
ferrin-polylysine conjugates in selected cell lines. Conjugate-DNA
complexes (6 ,ug ofpRSVL plus 12 .g of hTfpL19OB) were added to
CFT1, KB, HeLa, WI-38, and MRC-5 cells with or without adeno-
virus d1312 (1.0 x 104 viral particles per cell). Cell lysates were
analyzed for luciferase enzyme activity as before.
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target cells, suggesting that this effect is a function ofboth the
number of adenoviral cell-surface receptors characteristic of
each cell type, as well as the number of receptors for
transferrin.
DISCUSSION
The development of strategies to accomplish gene transfer by
the receptor-mediated endocytosis pathway has established a
vector system with special features and potentials. The
ability to accomplish gene delivery by means ofa physiologic
pathway has many advantages including (i) a nontoxic mech-
anism of transiting the eukaryotic cell membrane, (ii) the
capacity to administer DNA on a repetitive or continuous
basis, and (iii) the possibility of cell-specific targeting (7). In
addition, because the bifunctional molecular conjugate gene-
transfer vehicles are synthetically derived, the capacity to
prepare large amounts of these agents is feasible.
Gene-transfer efficiencies comparable or superior to those
obtained with conventional DNA-mediated gene transfer
vectors have been achieved using transferrin-polylysine con-
jugates (6, 7). The utility of this vector system in a given
context, however, is not predicted solely by the presence of
the appropriate cell-surface receptor, as extremely limited
gene transfer is noted for many target cells that possess
transferrin receptors (5, 6). It has been suggested that the
internalization of the conjugate-DNA complexes by means of
receptor-mediated endocytosis targets them for cellular path-
ways resulting in lysosomal degradation (5, 6). On this basis,
it was reasoned that inhibition of lysosomal enzymes would
increase the fraction ofDNA surviving transition through the
vesicle system of the cell. In this regard, augmentation of
gene transfer by transferrin-polylysine conjugates has been
demonstrated by the cotreatment of target cells with chloro-
quine, a lysosomatropic agent with pleotropic subcellular
effects. Unexpectedly, however, other agents employed to
inhibit lysosomal degradative functions, such as monensin,
were not effective in augmenting gene transfer, and, in fact,
functioned as inhibitors (6, 7). These conflicting findings raise
important questions as to whether the chloroquine effect is
exclusively on a lysosomatropic basis and, thus, whether
strategies to inhibit lysosomal enzymes will be generally
useful..
--The goal of allowing internalized conjugate-DNA com-
plexes to escape the endosome before lysosomal targeting led
us to explore the utility of adenoviral infection as a means to
augment gene transfer by this route. Adenoviruses enter cells
in a fashion analogous to the conjugate-DNA complexes;
after binding to specific cell-surface receptors the virions are
internalized by thb receptor-mediated endocytosis pathway
(18, 20). Unlike the conjugates, however, the adenovirus
possesses a specific mechanism to disrupt the endosome,
allowing escape to the cell cytosol; changes in endosome pH
during internalization expose hydrophobic domains of the
adenoviral capsid proteins, permitting them to interact with
the vesicle membrane in a fashion that ultimately disrupts its
integrity (21, 22). Once within the cell cytoplasm, uncharac-
terized mechanisms effect delivery of the virions to the
host-cell nucleus, where the viral genomicDNA is replicated.
As a consequence of their specific entry mechanisms,
viruses elicit major alterations in the cell membrane and
vesicle system of target cells. These changes have been
shown to be associated with altered cellular macromolecular
transport. In this regard, Fernandez-Puentes and Carrasco
(23) noted enhanced transport of administered protein toxins
in picornavirus-infected cells, an effect they attributed to
altered membrane permeability. Enhanced delivery of mac-
romolecules was also observed by means of the receptor-
mediated endocytosis pathway concomitant with adenoviral
infection (14, 16, 24). An important aspect of these studies
was the observation that adenoviruses enter cells by the
receptor-mediated endocytosis pathway and that they are
cointernalized with other receptor-bound macromolecules.
Thus, adenoviral-mediated disruption of the internalized
endosome augments release of its heterogeneous contents,
enhancing delivery to the cell cytosol ofother receptor-bound
cognates (14, 16, 24).
We wondered whether the capacity of adenovirus to dis-
rupt the endosome would enhance gene delivery by the
receptor-mediated endocytosis pathway. Coinfection with
adenovirus resulted in very significant augmentation of gene
transfer using transferrin-polylysine conjugates. The fact
that a replication-defective adenovirus could elicit this aug-
mentation ofgene transfer is consistent with the concept that
this phenomenon is based on the capacity ofthe virion to bind
target cells and be internalized and not on viral replicative
functions. Furthermore, the exposure of comparable quan-
tities of adenovirus d1312 to a K-562 cell line constitutively
expressing a Rous sarcoma virus long terminal repeat-
luciferase gene revealed no detectable change in luciferase
activity, whereas the adenovirus can function to enhance
delivery of pRSVL/polylysine-transfrrrin conjugates in the
parental K-562 line (data not shown). This result demon-
strates that the adenovirus enhancement of luciferase gene
expression is functioning at the level ofgene delivery and not
a transactivation phenomenon at the gene expression level.
These findings establish that gene transfer by transferrin-
polylysine conjugates is functionally limited by the absence
of specific mechanisms to accomplish conjugate-DNA-
complex release from the cellular vesicle system. In the
present study, this mechanism of endosome release was
provided by capitalizing on the specific entry functions of the
adenovirus mediating vesicle disruption. In this regard, it is
noteworthy that subversion of the highly efficient entry
mechanisms of the adenovirus is the rationale for the devel-
opment of recombinant adenoviruses as vectors to transfer
heterologous genes (25). The employment of these agents,
however, has been limited by intrinsic constraints on their
construction; relatively short heterologous DNA segments of
<6 kilobases can be incorporated into the recombinant
adenoviral genome (26), and expression of these introduced
genes is obligated by means of adenoviral regulatory signals
(27). The use ofadenoviruses in a facilitative fashion, as in the
present study; offers the advantages of efficient adenoviral
entry in combination with the advantages ofgene transfer by
transferrin-polylysine conjugates; DNA segments ofup to 15
kilobases, and possibly larger, can be transferred, and there
is no constraint on the functional design of the introduced
DNA.
Note Added in Proof. We recently demonstrated that UV-inactivated
adenovirus d1312 also functions to enhance receptor-mediated gene
delivery.
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